Safety Concerns Halt High-dose Tenecteplase Stroke Study Safety Concerns Halt High-dose Tenecteplase Stroke Study

The NOR-TEST 2A trial was stopped after increased rates of ICH and mortality were seen in the group assigned to tenecteplase 0.4 mg/kg compared with the standard dose of alteplase.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology News Source Type: news